INS and cancer: In the UKPDS, the cumulative incidence of cancer-related death over 11 years similar in insulin-treated patients was similar (4.9 versus 5.0%) to that observed in other treatment groups, which included metformin, sulfonylureas, and conventional nonintensified therapy [55, 56].